Table 3.
Associations of abnormal liver function tests and hepatitis B infection with risk of hematologic malignancies.
| Univariate model | Multivariate model* | ||
|---|---|---|---|
| Outcome | Abnormal LFT HR (95%CI) | Abnormal LFT HR (95%CI) | HBsAg+ HR (95%CI) |
| p-value | p-value | p-value | |
| ALT results | |||
| NHL |
1.29 (1.08–1.54) 0.005 |
1.22 (1.02–1.46) 0.03 |
1.70 (1.41–2.04) <0.0001 |
| Follicular NHL | 1.69 (0.79–3.62) 0.18 |
1.68 (0.77–3.66) 0.19 |
1.55 (0.65–3.71) 0.32 |
| DLBCL | 1.20 (0.86–1.66) 0.28 |
1.10 (0.79–1.53) 0.58 |
1.99 (1.46–2.72) <0.0001 |
| T-cell NHL | 0.47 (0.17–1.28) 0.14 |
0.45 (0.16–1.24) 0.12 |
1.50 (0.72–3.13) 0.28 |
| Other/unknown NHL |
1.43 (1.14–1.79) 0.002 |
1.36 (1.08–1.72) 0.009 |
1.58 (1.23–2.03) 0.0003 |
| Malignant immunoproliferation | 0.63 (0.08–4.84) 0.66 |
0.68 (0.09–5.34) 0.71 |
3.91 (1.08–14.2) 0.04 |
| Hodgkin lymphoma | 1.16 (0.65–2.08) 0.61 |
1.19 (0.66–2.15) 0.56 |
0.97 (0.47–2.00) 0.93 |
| Multiple myeloma | 1.02 (0.70–1.47) 0.94 |
1.05 (0.73–1.53) 0.78 |
0.89 (0.56–1.42) 0.63 |
| Lymphoid leukemia |
1.53 (1.00–2.35) 0.05 |
1.58 (1.02–2.43) 0.04 |
0.91 (0.50–1.64) 0.75 |
| Myeloid/monocytic leukemia | 1.15 (0.87–1.53) 0.33 |
1.15 (0.86–1.53) 0.34 |
1.19 (0.86–1.64) 0.30 |
| Other/unknown leukemia | 1.16 (0.77–1.75) 0.47 |
1.14 (0.75–1.73) 0.54 |
1.22 (0.77–1.94) 0.40 |
| AST results | |||
| NHL |
1.35 (1.10–1.66) 0.004 |
1.16 (0.94–1.42) 0.17 |
1.71 (1.42–2.06) <0.0001 |
| Follicular NHL | 1.80 (0.77–4.24) 0.18 |
1.70 (0.71–4.08) 0.23 |
1.56 (0.65–3.73) 0.32 |
| DLBCL | 1.36 (0.95–1.96) 0.10 |
1.13 (0.78–1.64) 0.51 |
1.99 (1.45–2.72) <0.0001 |
| T-cell NHL | 1.09 (0.47–2.51) 0.84 |
0.99 (0.42–2.29) 0.97 |
1.40 (0.67–2.93) 0.37 |
| Other/unknown NHL |
1.35 (1.03–1.77) 0.03 |
1.16 (0.88–1.52) 0.30 |
1.62 (1.26–2.08) 0.0002 |
| Malignant immunoproliferation | 2.08 (0.47–9.27) 0.34 |
1.85 (0.40–8.54) 0.43 |
3.55 (0.97–13.0) 0.06 |
| Hodgkin lymphoma | 0.88 (0.41–1.90) 0.75 |
0.82 (0.38–1.77) 0.61 |
1.01 (0.49–2.08) 0.98 |
| Multiple myeloma |
1.54 (1.07–2.22) 0.02 |
1.40 (0.97–2.03) 0.08 |
0.86 (0.54–1.38) 0.54 |
| Lymphoid leukemia |
2.21 (1.43–3.41) 0.0003 |
2.09 (1.35–3.25) 0.001 |
0.88 (0.48–1.59) 0.66 |
| Myeloid/monocytic leukemia |
1.44 (1.07–1.95) 0.02 |
1.32 (0.97–1.79) 0.08 |
1.17 (0.85–1.61) 0.34 |
| Other/unknown leukemia | 1.30 (0.82–2.05) 0.27 |
1.14 (0.72–1.82) 0.57 |
1.22 (0.77–1.94) 0.40 |
Abbreviations: LFT liver function test, HBsAg hepatitis B surface antigen, HR hazard ratio, CI confidence interval, ALT alanine aminotransferase, AST aspartate aminotransferase, NHL non-Hodgkin lymphoma, DLBCL diffuse large B cell lymphoma
Statistically significant results are underlined.
*
The multivariate model includes the specified liver function test abnormality, HBsAg positivity, and adjustment for sex, age at baseline, and calendar year at baseline.